Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 31, 2019
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
HAIFA, Israel, July 31, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, is presenting ...
July 31, 2019
OncoCyte to Report Second Quarter 2019 Financial Results on Wednesday, August 14, 2019
ALAMEDA, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, ...
July 31, 2019
Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7
SAN DIEGO, July 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, ...
July 31, 2019
Kiadis Pharma to present at upcoming conference in August 2019
Amsterdam, The Netherlands, July 31, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, ...
July 31, 2019
Onxeo S.A.: Publication of the 2019 Half-Yearly Financial Report
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting ...
July 31, 2019
Vermillion to Report Second Quarter 2019 Financial Results on August 8
AUSTIN, Texas, July 31, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will ...
July 31, 2019
TRACON to Report Second Quarter 2019 Company Highlights and Financial Results on August 7, 2019
SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
July 31, 2019
CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019
MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
July 31, 2019
Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update
HOPKINTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
July 30, 2019
CytoSorbents to Report Q2 2019 Operating and Financial Results
MONMOUTH JUNCTION, N.J., July 30, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and ...
July 30, 2019
Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference
SAN DIEGO and TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting ...
July 30, 2019
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced ...
July 30, 2019
Establishment Labs to Announce Second Quarter 2019 Financial Results on August 13, 2019
NEW YORK, July 30, 2019 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (ESTA), a medical technology company focused on women’s health, initially in the breast ...
July 30, 2019
Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed
REHOVOT, Israel and BRIDGEWATER, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
July 30, 2019
BioLineRx to Report Second Quarter 2019 Results on August 6, 2019
TEL AVIV, Israel, July 30, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial ...
July 30, 2019
Lipocine to Present at the Canaccord Genuity 39th Annual Growth Conference
SALT LAKE CITY, July 30, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, ...
July 30, 2019
Inventiva - H1 2019 Financial Information and Corporate Business Update
Daix (France), July 30, 2019 – Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
July 30, 2019
NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board
PITTSBURGH, July 30, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address ...
July 29, 2019
Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting
PALO ALTO, Calif., July 27, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...
July 29, 2019
Zealand Pharma announces change in corporate management
Copenhagen, Denmark, July 29, 2019 – Zealand Pharma A/S (“Zealand”) (ZEAL) (CVR-no. 20 04 50 78) announces that Andrew Parker will leave his position as ...
Page 14 of 169